On April 2, 2026, Ugwumba Chidozie, identified as a 10 percent owner of Clene Inc. (NASDAQ:CLNN), disposed of 24,925 shares of the company's common stock, according to a Form 4 filed with the Securities and Exchange Commission. The shares were sold at $4.81 apiece, producing proceeds of $119,889.
Following the transaction, Chidozie is recorded as owning 401,891 shares directly, held via SymBiosis II, LLC. Since the sale, the stock has traded higher, reaching $5.76. Data from InvestingPro cited in the filing indicates that despite a 114% gain over the last year, the shares are down 44% over the prior six months.
InvestingPro assigns Clene a "WEAK" financial health rating, and analysts referenced in the same data set do not expect the company to be profitable this year.
Beyond the insider sale, Clene reported two material developments related to CNM-Au8, its investigational treatment for amyotrophic lateral sclerosis (ALS). The U.S. Food and Drug Administration has granted the company an in-person Type C meeting to discuss recently generated biomarker data. The meeting will concentrate on new analyses that suggest reductions in neurofilament light chain - a biomarker associated with neuronal damage - may correlate with lower mortality risk in ALS patients. Clene has indicated that this evidence could potentially support the use of neurofilament light chain reduction as a surrogate endpoint to pursue accelerated approval for CNM-Au8.
In parallel with the regulatory engagement, Clene has arranged a registered direct offering of more than $28 million aimed at supporting development of CNM-Au8. The financing round lists participation from investment firms including Boxer Capital, Coastlands Capital and Vivo Capital, alongside existing insider investors. An initial tranche exceeding $6 million is expected to fund company operations into the third quarter of 2026.
Company materials note that this financing may carry the company through key near-term milestones, including the FDA's decision on whether to accept a New Drug Application for CNM-Au8. The combination of insider selling, a mixed short-term share price performance, an unfavorable financial health rating and simultaneous regulatory and financing progress frames the current state of Clene as one of active clinical and capital activity amid ongoing financial constraints.
Summary of factual points in this report is limited to the information disclosed in the Form 4 filing, InvestingPro data and Clene's announcements regarding the FDA meeting and registered direct offering.